Literature DB >> 20399064

Expression analysis of key somatotropic axis and liporegulatory genes in ghrelin- and obestatin-infused dairy cows.

T M Grala1, J K Kay, C G Walker, A J Sheahan, M D Littlejohn, M C Lucy, J R Roche.   

Abstract

Ghrelin, an orexigenic hormone, is the endogenous ligand for the growth hormone secretagogue receptor (GHSR). Obestatin is produced from the same precursor peptide as ghrelin, and although obestatin was initially thought to promote actions opposite to those of ghrelin, many studies have failed to confirm this hypothesis. In the current study, multiparous cows were continuously infused with ghrelin (n = 10) or obestatin (n = 10) for 8 wk and compared to an untreated group (n = 10) to examine the effects of these hormones on somatotropic and liporegulatory gene expression. The expression of key genes was measured by quantitative real-time polymerase chain reaction. Growth hormone secretagogue receptor mRNA expression was altered in ghrelin- and obestatin-infused cows in a similar manner, as expression was increased at 4 wk, however it had decreased by 8 wk. Obestatin-infused cows presented with a significant decrease in the expression of ATP-binding cassette A1 (ABCA1) in adipose tissue, suggesting changes in cholesterol transport. Liver insulin-like growth factor (IGF) binding protein-3 mRNA displayed a week-by-treatment interaction, as expression was increased in control and obestatin-infused cows; however, expression decreased in ghrelin-infused cows. Adipose expression of hormone sensitive lipase (LIPE) mRNA was not altered by treatment or time, suggesting hormone infusion is not initiating lipolysis. The expression of lipogenic genes in adipose tissue increased with time in all groups, consistent with the general lactational profile of lipogenesis in dairy cows. These data indicate that continuous infusion of ghrelin or obestatin does not alter the expression of key somatotropic or liporegulatory genes in the lactating dairy cow, although obestatin infusion may alter cholesterol transport.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399064     DOI: 10.1016/j.domaniend.2010.02.004

Source DB:  PubMed          Journal:  Domest Anim Endocrinol        ISSN: 0739-7240            Impact factor:   2.290


  5 in total

1.  The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling.

Authors:  Andrew J Agnew; Emma Robinson; Carmel M McVicar; Adam P Harvey; Imran H A Ali; Jennifer E Lindsay; Denise M McDonald; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Treatment of lean and diet-induced obesity (DIO) mice with a novel stable obestatin analogue alters plasma metabolite levels as detected by untargeted LC-MS metabolomics.

Authors:  Brian D Green; Stewart F Graham; Elaine Cowan; Praveen Kumar; Kerry J Burch; David J Grieve
Journal:  Metabolomics       Date:  2016-07-05       Impact factor: 4.290

3.  Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients.

Authors:  Anita Szentpéteri; Hajnalka Lőrincz; Sándor Somodi; Viktória Evelin Varga; György Paragh; Ildikó Seres; György Paragh; Mariann Harangi
Journal:  Lipids Health Dis       Date:  2018-03-05       Impact factor: 3.876

4.  Methyl 3,4-Dihydroxybenzoate Enhances Resistance to Oxidative Stressors and Lifespan in C. elegans Partially via daf-2/daf-16.

Authors:  Xiang-Nan Mi; Li-Fang Wang; Yang Hu; Jun-Ping Pan; Yi-Rong Xin; Jia-Hui Wang; Hai-Ju Geng; Song-Hui Hu; Qin Gao; Huan-Min Luo
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

Review 5.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.